RecruitingPhase 2Phase 3NCT07538583

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome

Sponsor

Quoin Pharmaceuticals

Enrollment

16 participants

Start Date

Mar 19, 2026

Study Type

INTERVENTIONAL

Conditions

Netherton Syndrome

Summary

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

Eligibility

Min Age: 4 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called QRX003 for people with netherton syndrome. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 4 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.